Log In
Print
BCIQ
Print
Print this Print this
 

R256

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionInhaled interleukin-13 (IL-13) signaling and JAK kinase (JAK) inhibitor
Molecular Target Interleukin-13 (IL-13) ; JAK kinase (JAK)
Mechanism of ActionJanus kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAsthma
Indication DetailsTreat chronic asthma
Regulatory Designation

Partner

AstraZeneca plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today